MRI-based personalisation of neoadjuvant chemotherapy duration in HER2-positive early breast cancer (TRAIN-3): primary results from a multicentre, single-arm, phase 2 study

Journal:

The Lancet Oncology

Published:

2026-02-16

DOI:

10.1016/s1470-2045(25)00707-7

Affiliations:

18

Authors:

19

Go to article

Institutions	Authors	Share
Netherlands Cancer Institute (NKI), Netherlands	10.500000 10.500000	0.55
Amsterdam UMC, Netherlands	1.000000	0.05
St. Antonius Hospital, Netherlands	1.000000	0.05
Isala Clinics, Netherlands	1.000000	0.05
Amphia Hospital, Netherlands	1.000000	0.05
Reinier de Graaf Hospital, Netherlands	1.000000	0.05
Hospital Group Twente (ZGT), Netherlands	1.000000	0.05
Spaarne Hospital, Netherlands	1.000000	0.05
Radboud University Medical Centre (Radboudumc), RU, Netherlands	0.500000	0.03
Leiden University Medical Center (LUMC), Netherlands	0.500000	0.03
Tilburg University, Netherlands	0.500000	0.03

Interested in Oncology and Carcinogenesis?